Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Kristina Krpina"'
Autor:
Kresimir Tomic, Dragana Karan Krizanac, Faruk Skenderi, Kristina Krpina, Andrea Carapina Bilic, Kristina Galic, Zoran Gatalica, Semir Vranic
Publikováno v:
Respiratory Medicine Case Reports, Vol 45, Iss , Pp 101920- (2023)
Small cell lung cancer (SCLC) is a highly aggressive malignancy with a poor outcome. We present the case of a 57-year-old male patient with extensive-stage (ES-SCLC) treated with chemotherapy and atezolizumab. A complete response was achieved with a
Externí odkaz:
https://doaj.org/article/bbad840544084114a4314397604fe863
Publikováno v:
Biomedicines, Vol 11, Iss 7, p 1982 (2023)
Small cell lung cancer (SCLC) is an aggressive malignancy characterized by rapid proliferation, early dissemination, acquired therapy resistance, and poor prognosis. Early diagnosis of SCLC is crucial since most patients present with advanced/metasta
Externí odkaz:
https://doaj.org/article/ba705e2f12544c4a9fd040f9c225d821
Autor:
Vrdoljak, Dora Čerina, Kristina Krpina, Marko Jakopović, Natalija Dedić Plavetić, Fran Seiwerth, Snježana Tomić, Jasna Radić, Ingrid Belac Lovasić, Ivana Canjko, Marijo Boban, Miroslav Samaržija, Eduard
Publikováno v:
Cancers; Volume 15; Issue 13; Pages: 3395
Non–small cell lung cancer (NSCLC) has become the best example of precision oncology’s impact on outcomes in everyday clinical practice, significantly changing the expectations of all stakeholders, including medical professionals, society, and mo
Publikováno v:
Journal of Clinical Medicine; Volume 11; Issue 22; Pages: 6695
Journal of clinical medicine
Volume 11
Issue 22
Journal of clinical medicine
Volume 11
Issue 22
Introduction: Lung cancer is one of the most diagnosed malignancies with increasing incidence worldwide. Immunotherapy is the main oncological treatment for advanced non-small cell lung cancer (NSCLC), for which the discovery of new efficient biomark
Autor:
Kristina Krpina, Marko Jakopović, Ante Marušić, Miroslav Samarzija, Fran Seiwerth, Lela Bitar
Publikováno v:
J Thorac Dis
Thymic epithelial tumors (TETs) are rare thymic neoplasms. There are approximately 1.5 cases per million TETs per year. They are the most common anterior mediastinal tumors in adults. Due to limited activity of available treatment options novel strat
Autor:
Marko Jakopović, S. Smojver Ježek, Kristina Krpina, Miroslav Samaržija, Fran Seiwerth, G. Glodić, A. Mataić, Lela Bitar, F. Džubur, Ivona Markelić
Publikováno v:
Journal of Thoracic Oncology. 16:S1075
Autor:
Lovorka Batelja, Miroslav Samaržija, Željko Djaković, Suzana Kukulj, Bernard Budimir, Marko Jakopović, Kristina Krpina
Publikováno v:
Lung cancer.
Autor:
Marko Jakopović, Kristina Krpina, Marta Korsic, Sonja Badovinac, Lela Bitar, Mihovil Roglić, Sanja Pleština, Ante Marušić, Fran Seiwerth, Miroslav Samarzija, Suzana Kukulj
Publikováno v:
Journal of Clinical Oncology. 38:e21110-e21110
e21110 Background: In extensive stage small-cell lung cancer (ES-SCLC) immune check-point inhibitors, atezolizumab and durvalumab, when combined with chemotherapy in the first-line setting show better efficacy than chemotherapy alone with safety prof
Autor:
Sanja Popović Grle, Ante Marušić, Kristina Krpina, Andrea Vukić Dugac, Blanka Cuk, Ivona Markelić
Publikováno v:
Clinical Problems.
Introduction: COPD is characterized by airway remodeling and loss of pulmonary parenchymal elasticity. Spirometry is not enough to differentiate the contribution of each. Emphysema and bronchial wall thickness are better assessed by quantitative anal
Autor:
J. Josip Grah, Miroslav Samaržija, Kristina Krpina, Marko Jakopović, Gordana Drpa, Lela Bitar, Fran Seiwerth, Blanka Cuk, Suzana Kukulj, Ante Marušić, Bernard Budimir
Publikováno v:
Lung Cancer.
Introducion: Lung carcinoid(LC)tumors account for 1–2% of all lung malignancies. They are classified as typical(TC)or atypical(AC)based on the mitotic index and/or the presence of necrosis. The utility of Ki-67 to differentiate between TCs and ACs